Workers with hemophilia are at a much higher risk of stroke, developing a joint disease, or needing a knee or hip replacement than the general population, Taiwanese researchers report. The study, “Risk of major comorbidities among workers with hemophilia: A 14-year population-based study,” was published in the journal…
Search results for:
Researchers report that the Medtep Hemophilia online platform helped hemophilia patients improve their adherence to preventive treatment, while increasing their quality of life and their perception of their illness. The study titled, “Effectiveness of the Medtep Hemophilia online platform for adherence to prophylactic treatment in haemophilia patients:…
One of the major hurdles people with hemophilia face is complying with their medication schedule — in particular, injecting themselves several times a week with clotting factor. MORE: Seven recommended books to learn more about hemophilia Clotting factor has a relatively short half-life (the time it takes for a person’s…
Sangamo Gets OK to Enroll UK Patients in Phase 1/2 Trial on SB-FIX, Potential Hemophilia B Therapy
A Phase 1/2 clinical trial on SB-FIX, an investigative gene-editing therapy for hemophilia B, is now authorized to enroll adult and adolescent patients in the U.K., Sangamo Therapeutics announced. Approval from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) will make this the first genome-editing study conducted in Europe. Once safety…
European Commission OKs Hemlibra to Preventively Treat Hemophilia A with Factor VIII Inhibitors
The European Commission has approved Hemlibra (emicizumab) for routine preventive treatment of bleeding episodes in people who have hemophilia A with factor VIII inhibitors. The antibody therapy is designed to restore the factor VIII, which is deficient in hemophilia A. Hemlibra is being co-developed by Japan’s Chugai Pharmaceuticals, Switzerland’s…
AGC Biologics to Produce Hemophilia B Clotting Factor That Catalyst Is Testing in Clinical Trials
AGC Biologics has agreed to produce the hemophilia B clotting therapy that Catalyst Biosciences is testing in clinical trials, the companies announced. The next step in testing CB 2679d will be a Phase 2b trial in the third quarter of 2018, according to Catalyst, which is based in South San Francisco.
A Guided Tour of Hemophilia Treatment Centers
In this video from BloodFeed – Hemophilia Bleeding Disorders Media, actor Brian Williams (who plays hematologist Dr. Young in the online comedy Stop the Bleeding) takes viewers on a tour of a hemophilia treatment center (HTC). MORE: Three tips for coping with a hemophilia…
Eloctate use in immune tolerance induction (ITI) therapy shows promise in high-risk patients with severe hemophilia A and inhibitors treated for the first time, Bioverativ announced. The results support a potential benefit for some patients who tried and failed ITI with other factors. The study, “Recombinant factor VIII…
In this video from the Hemophilia Federation of America, Kyle McCullough and Jesse Mayhan share what it’s like living with severe hemophilia. The boys discuss their treatment and what they tell friends when they ask about their condition. They also talk about what they’d like to…
The Oklahoma Medical Research Foundation (OMRF) and Shanghai RAAS Blood Products are working together on the development of new hemophilia and traumatic bleeding therapies. This is the first time OMRF has collaborated with a Chinese blood products manufacturer. In 2017, Shanghai RAAS was 25th on Forbes’ “Growth Champions”…